Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions
Borderline Personality Disorder
Interventions
DRUG

Lamotrigine

Subject in active active drug group will receive lamotrigine tablets 12.5 per day for the first week of the study. Dose of lamotrigine can be increased to 25mg per day during the second week of the study and may be increased each week thereafter for the next 9 weeks by 25mg per day. Subjects in active treatment group will receive lamotrigine for total of 12 weeks

DRUG

Placebo

Subjects will receive 12.5mg of inert placebo per day during the first week of the study. Inert placebo can be increased to 25mg per day during the second week of the study and by 25mg per day each week for the next 9 weeks. Subjects can receive a total of 12 weeks of placebo.

Trial Locations (1)

02478

McLean Hospital, Belmont

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Mclean Hospital

OTHER

NCT00634062 - Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder | Biotech Hunter | Biotech Hunter